Compare CAPR & MSBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CAPR | MSBI |
|---|---|---|
| Founded | 2005 | 1881 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 584.9M | 668.5M |
| IPO Year | 2011 | 2011 |
| Metric | CAPR | MSBI |
|---|---|---|
| Price | $9.37 | $33.63 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 8 | 3 |
| Target Price | ★ $44.63 | $24.33 |
| AVG Volume (30 Days) | ★ 9.1M | 126.0K |
| Earning Date | 05-12-2026 | 04-23-2026 |
| Dividend Yield | N/A | ★ 5.00% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.56 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $18.41 |
| Revenue Next Year | $3.31 | $2.07 |
| P/E Ratio | ★ N/A | $21.44 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.96 | $14.24 |
| 52 Week High | $40.37 | $35.10 |
| Indicator | CAPR | MSBI |
|---|---|---|
| Relative Strength Index (RSI) | 49.13 | 58.49 |
| Support Level | $3.66 | $33.04 |
| Resistance Level | $30.39 | $35.10 |
| Average True Range (ATR) | 1.21 | 0.72 |
| MACD | 0.87 | -0.06 |
| Stochastic Oscillator | 68.14 | 83.08 |
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
Midland States Bancorp Inc is a diversified financial holding company. The company provides a full range of commercial and consumer banking products and services, business equipment financing, merchant credit card services, trust and investment management, and insurance and financial planning services. The Banking segment, which generates the majority of the revenue, provides financial products and services to consumers and businesses, including commercial, commercial real estate, mortgage, and other consumer loan products; commercial equipment financing, etc. The Wealth Management segment consists of trust and fiduciary services, brokerage, and retirement planning services. The Corporate segment includes the holding company's financing and investment activities, administrative expenses.